Trial of HT-100 in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD)

Trial Profile

Trial of HT-100 in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Halofuginone (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Mar 2017 Trial focus and secondary endpoints assumed based on purpose of trial.
    • 24 Mar 2017 New trial record
    • 22 Mar 2017 According to an Akashi Therapeutics media release, company has recieved FDA clearance for clinical development of HT-100 in patients with any of the genetic mutations that cause DMD.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top